Sylvia Adams, MD
The metastatic triple-negative breast cancer (TNBC) space, which typically has a short survival prognosis, is advancing through the introduction of novel treatment strategies, involving antibody-drug conjugates, PARP inhibitors, and immunotherapy, said Sylvia Adams, MD.
"The landscape is very much changing in TNBC," said Adams. "Up until 1 or 2 years ago, we only had chemotherapy. With that, the outcomes were dismal with, 1 year, or maybe one and a half years, for survival; but now we have new agents."
... to read the full story